← ANALYST RATINGS · TIPRANKS
Omnicell (OMCL): analyst forecast and price target
Analyst consensus
Strong Buy7 Buy0 Hold0 Sell
Ratings of 7 analysts in the last 3 months12-month forecast
Based on 7 price targets given in the last 3 months, the average target is $56.00, the highest $65.00, the lowest $45.00. The average is +58.2% from the last price of $35.39.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Allen Lutz★★★★★★★★★★#598 · hits 67% · avg +12.3% | Bank of America Securities | — | Buy | — | Reiterated | 16.10.26on TipRanks 12:25 | −0.5% | ↗ |
| Stan Berenshteyn★★★★★★★★★★#11485 · hits 50% · avg −5.0% | Wells Fargo | $50.00 | Buy | +41.3% | Assigned | 14.10.26on TipRanks 05:55 | −1.8%next day +1.3% | ↗ |
| AI xAi Medical - Healthcare Information ServicesxAI Grok-3 | TipRanks - xAI | $40.00 → $35.00−12.5% | Hold | −1.1% | Reiterated | 21.09.26on TipRanks Sep 20 23:06 | — | |
| AI DeepSeek Medical - Healthcare Information ServicesDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $40.00 → $34.00−15.0% | Hold | −3.9% | Reiterated | 21.09.26on TipRanks Sep 20 23:06 | — | |
| AI OpenAI Medical - Healthcare Information ServicesOpenAI 5.2 | TipRanks - OpenAI | $40.00 → $34.00−15.0% | Hold | −3.9% | Reiterated | 21.09.26on TipRanks Sep 20 23:06 | — | |
| AI Anthropic Medical - Healthcare Information ServicesAnthropic Opus-4.5 | TipRanks - Anthropic | $37.00 → $32.00−13.5% | Hold | −9.6% | Reiterated | 21.09.26on TipRanks Sep 20 23:06 | — | |
| AI Google Medical - Healthcare Information ServicesGemini 3-pro | TipRanks - Google | $40.00 → $34.00−15.0% | Hold | −3.9% | Reiterated | 21.09.26on TipRanks Sep 20 23:06 | — | |
| Matt Hewitt★★★★★★★★★★#3011 · hits 47% · avg +4.1% | Craig-Hallum | — | Buy | — | Reiterated | 02.09.26on TipRanks Sep 3 10:20 | +0.1%next day −0.7% · 5 days −6.1% | ↗ |
| Scott Schoenhaus★★★★★★★★★★#12104 · hits 35% · avg −9.7% | KeyBanc | $65.00 | Buy | +83.7% | Reiterated | 24.08.26on TipRanks 09:15 | −2.3%next day −4.5% · 5 days +1.0% | ↗ |
| AI PerPlexity Medical - Healthcare Information ServicesPerPlexity SonarPro | TipRanks - PerPlexity | $40.00 → $38.00−5.0% | Hold | +7.4% | Reiterated | 20.08.26on TipRanks 00:05 | — | |
| Jessica Tassan★★★★★★★★★★#11189 · hits 43% · avg −3.3% | Piper Sandler | $55.00 → $45.00−18.2% | Buy | +27.2% | Reiterated | 03.08.26on TipRanks 07:15 | +5.0%next day −3.1% · 5 days −2.9% | ↗ |
| Eugene Mannheimer★★★★★★★★★★#3417 · hits 51% · avg +6.8% | Freedom Capital Markets | $64.00 → $60.00−6.2% | Buy | +69.5% | Reiterated | 31.07.26on TipRanks Sep 27 04:50 | −5.4%next day +5.0% · 5 days +0.6% | ↗ |
| Bill Sutherland★★★★★★★★★★#3449 · hits 43% · avg +4.2% | Benchmark Co. | $60.00 | Buy | +69.5% | Reiterated | 30.07.26on TipRanks 08:31 | −12.0%next day −5.4% · 5 days −6.2% | ↗ |
| David Larsen★★★★★★★★★★#12072 · hits 35% · avg −4.7% | BTIG | — | Hold | — | Reiterated | 28.04.26on TipRanks Apr 29 06:06 | +21.4%next day −5.3% · 5 days −6.0% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Omnicell
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $56.00 at a price of $34.05 (+64.5%); now: $56.00 at $35.39 (+58.2%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 6 | 5 | 5 | 4 | 1 |
| Buy | 5 | 5 | 5 | 6 | 6 | 4 |
| Hold | 1 | 1 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 29.10.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $0.42 (from $0.35 to $0.53). Last quarter: $0.94.
Sales
Next quarter’s sales estimate — $304M (from $302M to $306M). Last quarter: $312M.
Best top-analyst consensus in the sector · Healthcare
About Omnicell
- CEO: Randall A. Lipps
- Employees: 3,485
- 4220 North Freeway, Fort Worth, TX, 76137, US
- www.omnicell.com
Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally. It offers hospital and health systems solutions, such as points of care for clinician workflows in patient care areas of the healthcare system; Titan XT, an automated dispensing system; XTExtend, a console swap for its XT cabinets; and Central Pharmacy Dispensing Service for the medication dispensing process. The company also provides Central Med Automation Service for medication dispensing; IV Compounding Service, an in-house compounding system; specialty pharmacy services, including turnkey solution to help health systems establish, manage, and optimize an entity-owned specialty pharmacy; EnlivenHealth platform to digitally enable retail and community pharmacies; medication adherence solutions comprising consumables and medication packaging systems; and technology implementation, customer education and training, program management, and related offerings to professional services. In addition, it offers post-installation support and maintenance via phone and/or web, on-site service, parts, and access to software upgrades; software and hardware products for full traceability of medicines and medical supplies throughout the healthcare system; OmniSphere, a cloud-based platform. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.
Data from the stock’s TipRanks forecast page, read 103 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗